Research Study

Cross-vaccination Study of GSK Biologicals' Lyophilized Formulation of the Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies
Principal Investigator 
Jan P. Dutz

Overview

Body Locations and Systems 
Shingles
ClinicalTrials.gov# 
NCT02690207
Status 
Recruiting
Study Start/End 
Oct 27, 2016 to Oct 27, 2017
Locations 
Diamond Health Care Centre
Name/Title 
Tanya Saran, Research Coordinator
Phone 
604-875-4111 ext.62178
Email Address 
tanya.saran@vch.ca
Purpose of Study 

The purpose of this study is to cross-vaccinate and collect safety data in terms of unsolicited Adverse Events (AEs), Serious Adverse Events (SAEs) and potential Immune Mediated Disease (pIMD) from subjects >= 50 Years of age (YOA) who previously received placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229).

Eligibility 

Visit ClinicalTrials.gov for more information. 

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.